s estimated to be US$315.4 billion in 2005, including US$105 billion for informal care, which is nonprofessional care, usually provided by family members (37 percent of the total). Seventy-seven (77) percent of the total costs occur in the more developed regions that have 46 percent of the prevalence. Worldwide prevalence may quadruple to nearly 120 million by 2050, according to Wimo.
The 2005 prevalence estimate for Singapore was 22,000 people with dementia. Indonesia, 600,000; Malaysia, 60,000; Myanmar, 130,000; Philippines, 175,000; Thailand, 250,000; Viet Nam, 275,000.
The estimate for total societal cost of dementia (direct costs plus informal care) in 2005 for Singapore was US$391 million. Indonesia, US$2,128 million; Malaysia, US$511 million; Myanmar, US$118 million; Philippines, US$601 million; Thailand, US$1,330 million; Viet Nam, US$751 million. At the ADI conference, Wimo will present additional regional and country specific cost estimates, alternative cost estimates of informal care, and new cost estimates for Europe from the Eurocode project.
"Worldwide costs for dementia are enormous," Wimo says. "In light of the rapidly growing future prevalence estimates, in particular in less developed regions, the economic impact of dementia is a great challenge for every society."
Direct costs as well as costs of informal care were estimated by combining prevalence estimates, country and region specific data on Gross Domestic Product per person, and average wage with results from previously published cost-of-illness studies in different countries.
The Global Impact of Dementia
At the conference, Professor Martin Prince, of the Centre for Public Mental Health, Institute of Psychiatry, King's College, London will address "The Global Impact of Dementia" in a plenary immediately after the talk by Professor Wimo. Prince leads the 10/66 Dementia Research Group
Page: 1 2 3 4 5 6 Related medicine technology :1
|SOURCE Alzheimer's Disease International|
Copyright©2009 PR Newswire.
All rights reserved
. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV2
. Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test3
. Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments4
. BBK Worldwide Celebrates 25th Anniversary of Industry Leadership Through Innovation in Patient Enrollment5
. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University6
. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies7
. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development8
. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology9
. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol10
. New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy11
. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia